MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression. This review will highlight our current understanding of miRNA biogenesis and mechanisms of action, and will summarize recent work on the role of miRNAs, including the miR-29 family, in bone remodeling. These studies represent the fi rst steps in demonstrating the importance of miRNAs in the control of osteoblast and osteoclast diff erentiation and function. An in-depth understanding of the roles of these regulatory RNAs in the skeleton will be critical for the development of new therapeutics aimed at treating bone loss and perhaps facilitating fracture repair.
Introduction
Transcription factors, RNA binding proteins, and microRNAs (miRNAs) are among the factors that must act coordinately to control gene expression networks important for cellular function [1] . Following transcription, mRNAs are subject to the processes of splicing, nuclear export, traffi cking, and polyadenylation, followed by translation initiation and elongation. Each of these processes represents a point at which expression can be regulated, allowing for fi ne-tuning in response to chang ing environmental conditions. miRNAs are short (approximately 21-nucleotide) non-coding RNAs that regulate trans cript localization, polyadenylation, and translation. miRNAs are direct negative regulators of gene expression that bind to specifi c sequences within a target mRNA [2, 3] .
miRNAs were discovered as a result of studies aimed at identifying genes that mediate developmental transitions in Caenorhabditis elegans [4, 5] . Recent years have seen signifi cant advances in the miRNA fi eld, including the characterization of the miRNA biogenesis pathway, identi fi cation of the mechanisms by which miRNAs regulate gene expression, and an appreciation of how families of miRNAs can regulate cellular processes and contribute to disease phenotypes.
Th e goal of this review is to highlight our current under standing of miRNA biogenesis and mechanisms of action, and to summarize recent studies on the role of miRNAs in bone remodeling.
miRNA biogenesis
Th e miRNA biogenesis pathway has several steps: transcription, pri-miRNA processing, transport to the cytoplasm, precursor miRNA (pre-miRNA) processing, strand selection, transcript targeting, and transcript fate ( Figure 1 ). Th is rigorous, multistep processing pathway helps ensure that only RNAs with the correct structures and sequences are able to regulate gene expression.
miRNA genes are found on every chromosome in humans, except for the Y chromosome. Like the promoters of protein-coding genes, miRNA promoters are regulated by epigenetics and by transcription factors. miRNA genes are transcribed by RNA polymerase II or III, from independent miRNA genes, or from the introns of protein-coding or non-protein-coding genes [6, 7] ( Figure 2) . Th e initial product of miRNA gene transcription is the primary transcript (pri-miRNA), which may be several thousand nucleotides long. Multiple miRNAs may be co-transcribed in a single pri-miRNA. Th e entire pri-miRNA is capped and polyadenylated, like mRNA transcripts. Tandem transcription of several miRNAs, possibly along with protein-coding genes, allows the genes to be expressed together. Th ese coexpressed genes may interact within the same pathway or through crosstalk between pathways. Th e co-expression of miRNA and protein-coding genes may also function to ensure negative feedback on the protein-coding gene to prevent its over-expression [8] .
In mammals, the pri-miRNA is processed within the nucleus by the Drosha-DiGeorge syndrome critical region gene 8 (DGCR8) complex ( Figure 1 , in nucleus). Drosha is an RNase III-type endonuclease, and DGCR8 is thought to recruit and bind the transcript [9] . Th e Figure 1 . MicroRNA biogenesis pathway. miRNAs are transcribed by RNA polymerase (Pol) II or III into primary (pri)-miRNAs, which are processed by Drosha/DGCR8 (DiGeorge syndrome critical region gene 8) into precursor (pre)-miRNAs. The mature miRNA strand is highlighted in red. The premiRNA is transported from the nucleus into the cytoplasm by Exportin 5, where it is then processed by Dicer/TRBP (Dicer-TAR RNA binding protein) into a miRNA duplex. The duplex is unwound by a helicase and the mature strand (red) is incorporated into the RNA-induced silencing complex (RISC). Depending on miRNA complementarity to a target mRNA, the RISC mediates down-regulation of gene expression by either translational repression or mRNA degradation. Ago, Argonaute; PACT, protein activator of PKR; P-body, processing body.
the RNA-induced silencing complex (RISC). Th e RISC includes Dicer, TRBP, PACT (protein activator of PKR), and one of four Ago proteins [16] . Th e miRNA duplex is unwound by helicases into two single strands, the mature guide strand (miRNA; red strand in Figure 1 ) and the complementary passenger strand (miRNA*) [14] . Guide strand selection is dependent on the fi rst 5' nucleotides and which Ago protein is present in the RISC [17] .
Th e miRNA* is typically degraded by the RISC, although some miRNAs* are thought to negatively regulate gene expression, like a mature miRNA. It is not known why some miRNAs* are functional. One hypothesis is that the strands could be used diff erently in response to extracellular or intracellular cues, to regulate a more diverse set of protein-coding genes as needed, or strand selection could be tissue specifi c [18] . Strand selection also limits regulation by miRNAs* generated from highly expressed precursors.
While the mechanisms regulating miRNA biogenesis have been well studied, the regulation of miRNA stability, particularly in vertebrates, is not well understood. It is known that mature miRNA abundance is sensitive to Ago protein levels, suggesting that association with Ago can protect miRNAs from degradation [19] . Although most miRNAs appear to be stable, they do possess diff erential stability. One miRNA, miR-122, was recently shown to be stabilized by the addition of a single adenosine to its 3' end through the activity of the cytoplasmic poly(A) polymerase GLD-2. In contrast, uracils at positions 9 to 11 are important for the short half-life of miR-29b [15] . miR-382 also has a short half-life, due to sequence elements in the 3' end of the miRNA. Th e exosome 3'-5' exonuclease complex was shown to be important for miR-382 decay [20] . Discovery and characterization of cis-and trans-acting factors regulating miRNA stability is a topic of intense study.
miRNA functions
Once the RISC contains the guide strand, it delivers the miRNA to the target mRNA, where base pairing occurs. Most miRNA binding sites lie within the 3' UTR, although there are some reports of miRNAs binding in the 5' UTR and coding region of mRNAs [21, 22] . Th ere appears to be a biological basis for the preferential interaction of miRNAs with the 3' UTR. Data suggest that miRNA binding sites within the coding region of a transcript are less eff ective at mediating translational repression. Th is is likely due to the ability of ribosomal complexes to override and inhibit the interaction of the miRNA-RISC with the potential binding site(s) [23] . Similarly, relatively few functional miRNA binding sites are located in the 5' UTR of a transcript. Th e scanning activity of the ribosome may impair the interaction of the miRNA-RISC with the 5' UTR, suggesting there would be ineffi cient inhibition of gene expression. Although the general location of a miRNA binding site within the transcript helps defi ne the degree of repression mediated by miRNAs, other factors contribute to effi cacy. Th ese factors include the sequence context of the miRNA binding site, the number of target sites within the mRNA, the local RNA structure, and distance between target sites [24] [25] [26] [27] .
Th e degree of base pairing between the miRNA and its target determines the fate of the transcript. Of particular importance is the interaction between the 'seed' region of the miRNA (nucleotides 2 to 8) and the 3' end of the trans cript's miRNA binding site. Th e seed region nucleates miRNA binding. If there is perfect binding between the miRNA and target, the mRNA target is cleaved by the endonuclease Ago2, possibly in RNA processing bodies (P-bodies) [28, 29] . However, most metazoan miRNAs bind imperfectly to their targets, triggering translational repression. In such cases of imperfect miRNA-mRNA binding, there is frequently a bulge between the miRNA and its target, between the 9th and the 11th nucleotide of the miRNA, which induces translational suppression [30] .
For a majority of mRNAs, translation initiation occurs when the 5'-cap m7GpppN is recognized by eIF4E, a component of the eukaryotic translation initiation factor eIF. Th is complex also includes eIF4G, which interacts with eIF3, to recruit the 40S ribosomal subunit, and with polyadenylate-binding protein 1 (PABP1). Th e interaction of eIF4G with both eIF4E and PABP1 physically brings the 5' and 3' ends of the mRNA close together, stimulating translation initiation by increasing affi nity of eIF4E for the 5'-cap. Trans-acting factors that bind the 3' UTR inhibit translation by recruiting proteins that block the eIF4E-eIF4G interaction or that bind to the 5'-cap, preventing assembly of the 40S ribosome initiation complex [31] . Several studies have shown this to be the case for components of the RISC, specifi cally Ago proteins [32, 33] . Th e central domain of the Ago protein family has some sequence homology to the eIF4E cap-binding domain. Mutation of these residues in Ago proteins abolishes translational repression of m7G mRNAs, suggest ing that Agos can compete with eIF4E to inhibit translation [34] . miRNAs can also repress translation at post-initiation steps. miRNA-RISC can bind to actively translating mRNAs, reducing translational elongation and/or enhancing termination, concomitant with a reduction in ribosomal initiation and nascent peptide destabilization. As a component of the RISC, Ago proteins 1, 3, and 4 are thought to mediate post-initiation inhibition [35, 36] .
Initial studies of miRNA targets suggested that only the protein levels of regulated targets were decreased, whereas the levels of target mRNAs themselves were not aff ected. However, altering miRNA expression in cells or tissues can cause signifi cant changes in target mRNA levels, suggesting that miRNAs can induce mRNA destabilization [29, 37] . In eukaryotes, mRNA degradation can occur when there is a shortening of the poly(A) tail. As part of the RISC, Ago proteins 1, 3, and 4 are thought to repress translation by promoting poly(A) tail-mediated degradation [38] . One study demonstrated that miRNAmediated deadenylation of maternal mRNAs is necessary during zebrafi sh embryogenesis [37] .
Further, miRNAs function in P-bodies by sequestering target transcripts for storage, decapping, deadenylation, and degradation [28] . Interestingly, P-bodies may also act as a temporary storage space for translationally repressed mRNAs. Since most P-body components are also found dispersed in the cytosol, it is likely that repression by these proteins is initiated in the cytosol, and the repressed mRNAs then aggregate to form the P-body. Stress granules are another type of body containing repressed mRNAs, and they accumulate in response to stress conditions or general inhibition of translation [39] .
Bone remodeling
Th e skeleton is continuously remodeled throughout the lifetime of an individual, and this remodeling is a dynamic process by which bone resorption is coupled to bone formation, to replace damaged bone or to respond to metabolic needs [40] . To provide some context in which to appreciate the function of miRNAs in the skeleton, we will briefl y consider the steps of bone remodeling and the signals important for osteoclast and osteoblast maturation.
Bone remodeling, or turnover, is mediated by the delicate balance of osteoblast and osteoclast numbers and activities ( Figure 3 ). Osteoclasts resorb bone, whereas osteoblasts synthesize new bone. Th e release of cytokines at the site of remodeling recruits osteoclasts to the bone surface. Th e osteoclasts form a ruffl ed boarder that allows their tight adherence to the bone surface. Th e space between the osteoclast and the underlying bone becomes an isolated microenvironment into which the osteoclast's proton pump releases ions that generate an acidic environment, dissolving the mineralized component of the bone matrix. Th e organic matrix becomes exposed and is subsequently degraded by cathepsin K [41] . Th e reversal phase of bone remodeling begins with mononuclear cells preparing the bone surface for new osteoblasts and providing signals to recruit them. Early osteoblasts proliferate and secrete an extracellular matrix abundant in type I collagen. As the osteoblasts continue to diff erentiate, the matrix matures and is mineralized. Once the bone surface is restored, mature osteoblasts can undergo apoptosis or terminally diff erentiate into either bone surface lining cells or osteocytes, which are embedded in the calcifi ed matrix and are responsive to mechanical stresses [42] .
Diff erentiation of osteoclasts and osteoblasts from multipotent precursors is a critical component of bone turnover. Osteoclasts are derived from the monocyte/ macrophage lineage. Diff erentiation into osteoclasts is dependent on multiple extracellular signaling molecules, including macrophage colony-stimulating factor (MCSF), receptor activator for nuclear factor κB ligand (RANKL), tumor necrosis factor, interferon gamma, and interleukins [41] .
Osteoblasts are derived from mesenchymal stem cells (MSCs), which can diff erentiate into osteoblasts, adipocytes, chondrocytes, or myocytes, depending on the activation or inhibition of specifi c signaling pathways [43] . Some of the most important signaling molecules regu lat ing osteoblastic diff erentiation include bone morpho genetic proteins (BMPs), transforming growth factor (TGF)-β, WNT, Hedgehog, parathyroid hormone, insulin-like growth factor-1, fi broblast growth factors, and Notch.
Misregulation of osteoclastic or osteoblastic diff erentia tion could result in dysregulation of bone balance and pathological consequences, including osteoporosis. miRNAs have been shown to regulate osteoblast and osteoclast diff erentiation and function. Th e following section will summarize the known roles of miRNAs in osteoblast and osteoclast biology.
miRNAs in osteoblasts
Cell type-specifi c deletion of Dicer in committed osteoprogenitors results in embryonic lethality at embryonic day (E)14.5 [44] . Th e mutant embryos display a deformed cartilaginous skeleton, and a lack of bone formation. Th is study used the rat 2.3-kb Col1a1 promoter driven-Cre construct to delete the fl oxed Dicer alleles, and this Cre construct is transiently expressed during embryonic develop ment, likely causing the embryonic lethality. Th ese data reinforce the concept that Dicer-mediated miRNA processing is critical for osteogenesis.
Targeted deletion of Dicer in mature osteoblasts, using an osteocalcin-Cre construct, led initially to delayed perinatal bone formation, with a subsequent increase in postnatal bone acquisition [44] . In these mice, signifi cant increases in cortical and trabecular bone volume were evident at 4 months of age, and persisted to 8 months. Long bone from mice lacking Dicer expression in mature osteoblasts had increased levels of mRNA for type I collagens, RANKL, and tartrate-resistant acid phosphatase (TRAP). Although data on osteoblast and osteoclast number were not reported, these results suggest increased bone remodeling in the mutant mice. In contrast, another group deleted Dicer in mature osteo blasts using a mouse 2.3-kb Col1 promoter driven-Cre construct, and reported no eff ect on bone phenotype [45] .
Comparing these two studies, it is likely that diff erences in the degree of Cre-mediated recombination and cell type specifi city had an impact on the resulting mouse phenotypes. Nevertheless, these data suggest that Dicer activity is important for controlling both early and late bone cell diff erentiation programs.
In vitro knockdown of Dicer or Drosha in human MSCs inhibited osteogenic diff erentiation, confi rming similar eff ects in human cells [46] . Indeed, since Dicer is important for the processing of many miRNAs, dramatic eff ects on cell diff erentiation with Dicer ablation are not unexpected. However, Dicer-independent mechanisms for miRNA maturation have recently been described [47] . It will be interesting to consider how these mechanisms may impact skeletal phenotype and to identify which miRNAs are regulated by these alternative pathways.
Th e BMP signaling pathway plays a prominent role in promoting osteoblast diff erentiation and bone formation [48] . Several studies have focused on miRNAs modulated by BMP signaling as a means to understand the role of miRNAs in osteoblasts. From these studies, it is clear that a panel of BMP-regulated miRNAs is important for the regulation of osteoblast diff erentiation. Since some miRNAs can be co-expressed and/or co-regulated, it is possible that families of miRNAs may promote one pheno type at the expense of another. Th is appears to be the case for miR-133 and miR-135, which are downregulated during BMP-2-induced osteoblastic diff erentiation of C2C12 premyogenic cells, but are upregulated in these cells during myoblastic diff erentiation [49] . Over-expression of miR-133 or miR-135 blocked the BMP-mediated induction of osteoblastic markers, such 
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as alkaline phosphatase (ALP), osteocalcin, and HOXA10. Further studies demonstrated that Runx2 is a target for miR-133, and Smad5 is a target for miR-135. Runx2 is a transcription factor essential for osteoblast diff erentiation, whereas Smad5 is an intracellular Runx2 coreceptor [50, 51] . Th e concomitant down-regulation of these two miRNAs by BMP-2 likely plays an important role in the up-regulation of Runx2 and Smad5 during osteogenic diff erentiation.
Similarly, miR-206 is decreased in response to BMP-2 in C2C12 cells and during diff erentiation of primary murine osteoblasts [52] . Over-expression of miR-206 inhibits ALP activity, and Connexin 43 (Cx43) was shown to be a target of miR-206. Cx43 is a gap junction protein necessary for osteoblast diff erentiation and function [53] . In vivo, miR-206 is highly expressed in muscle and perichondrial osteoblasts at E14.5, is moderately expressed in bone collar cells at E16.5, and is undetectable in bone at E18.5. Transgenic mice expressing miR-206 in mature osteoblasts display a low bone mass phenotype, particularly evident in the trabecular compartment. Bone formation rate was decreased in the transgenic mice, suggesting a defect in osteoblast function, whereas the osteo clast surface was unchanged. Th ese data confi rm miR-206 as a negative regulator of osteoblast function.
Th e sequences of mature miR-141 and miR-200a are very similar, and these two miRNAs are decreased in BMP-2-treated MC3T3-E1 osteoblastic cells. miR-141 and -200a appear to be negative regulators of osteoblast diff eren tiation, since their over-expression inhibits this process. Dlx5 (Distal-less homeobox 5) is a master osteogenic transcription factor, and the 3' UTR for Dlx5 has a potential binding site for miR-141 or -200a [54] . In cells over expressing miR-141 or -200a, Dlx5 protein levels were decreased. Since Dlx5 activates the trans cription of osterix, a transcription factor crucial for osteoblast diff er entiation, it is possible that the BMP-2-induced repres sion of miR-141 and -200a expression may indirectly augment the transcription of osterix, to promote osteo blastogenesis [55] .
BMP-2 was also shown to decrease the expression of miR-208 [56] . Over-expression of miR-208 antagonized the BMP-2-mediated osteoblastic diff erentiation of MC3T3-E1 cells and primary mouse osteoblasts. Th e osteogenic transcription factor Ets1 was shown to be a target of miR-208. Ets1 stimulates the transcription of osteopontin and Runx2, and this was inhibited by miR-208 over-expression [56, 57] . Th us, BMP-2 decreases miR-208 expression, allowing up-regulation of Ets1 and promoting osteoblastic diff erentiation.
In ST2 mouse mesenchymal cells, miR-125b expression is decreased after a 6-day treatment with BMP-4. miR125b has a negative eff ect on osteoblastic diff erentiation, as over-expression of miR-125b decreased ALP activity and knockdown of miR-125b increased ALP. Potential targets for miR-125b in osteoblasts have not been validated; however, miR-125b may play a role in regulating cell proliferation [58] . In contrast, miR-210 was found to be increased during BMP-4-induced osteoblastic diff erentiation of ST2 cells [59] . miR-210 plays a positive role in osteoblast diff erentiation. Transcripts for ALP and osterix were increased in ST2 cells over-expressing miR-210. Activin A receptor type 1B (AcvR1b) was identifi ed as a target of miR-210. AcvR1b is essential for activin signaling, which may play a role in repressing osteoblastic diff erentiation [60] .
Commitment of mesenchymal cells to a particular lineage depends on intracellular and extracellular cues to guide diff erentiation. miR-204 is induced during the adipo genic diff erentiation of murine C3H10T1/2 cells and human MSCs. Concomitantly, Runx2 is decreased. Runx2 is a target for miR-204. Over-expression of miR-204 negatively regulates Runx2 expression, inhibits osteoblast diff erentiation, and promotes adipocyte diff erentiation [61] . Runx2 can also be negatively regulated by some members of the miR-23a/27a/24-2 cluster in murine osteoblasts [62] . Th e cluster is up-regulated during diff eren tiation of rat osteoblasts, but only miR-23 appears to directly target the Runx2 3' UTR.
During terminal osteoblastic diff erentiation of human adipocyte-derived stem cells, miR-26a expression is increased. Further, as miR-26a increases, SMAD1 levels decrease. SMAD1 was shown to be a target for miR-26a, and knockdown of miR-26a increased the expression of osteoblast maker genes, including those encoding COL1A1, osteopontin, and osteocalcin [63] . SMAD1 is a critical downstream mediator of BMP signaling, and increased expression of SMAD1 augments osteoblasto genesis.
miR-199a and -346 are up-regulated during osteoblastic or adipogenic diff erentiation of human MSCs [46] . Th ese miRNAs negatively regulate leukemia inhibitory factor (LIF), which is a marker for human MSC multipotency, and is associated with the uncommitted state of embryonic and adult stem cells [64] . Indeed, expression of LIF is decreased as stem cell plasticity is decreased. Th e inhibition of LIF by miR-199a and -346 in human MSCs likely contributes to the induction of diff erentiation.
Th e miR-29 family is one of the best characterized miRNA families with regard to osteoblast function, and these miRNAs are important positive regulators of osteoblast diff erentiation. Th e expression of miR-29 family members is low during the early, matrix deposition phases of osteoblastogenesis. A low level of miR-29 expression is important at this time since miR-29 targets bone matrix RNAs, including COL1A1, COL3A1, and osteonectin (ON)/SPARC (secreted protein acidic and rich in cysteine) [65, 66] . Th e co-regulation of osteonectin and fi brillar collagens is not unexpected, since osteo nectin plays a critical role in regulating collagen fi bril formation [67] .
Later, the expression of miR-29 is increased as the matrix matures and the osteoblast achieves terminal maturation. Th is increase in miR-29 likely plays a role in the time-dependent suppression of collagen synthesis, which may be necessary to prevent fi brosis, and to allow for subsequent mineral deposition and proper fi bril alignment, both of which are necessary for normal bone turnover [68, 69] . Over-expression of miR-29 family members promotes osteoblastic diff erentiation, whereas knockdown of miR-29 decreases diff erentiation markers. It is interesting to note that other validated targets for miR-29, important in osteoblast function, include several proteins that are inhibitors of osteoblast diff erentiation, such as histone deacetylase (HDAC)4, TGFβ3, AcvR2A, CTNNBIP1 (catenin beta interacting protein I), and DUSP2 (dual specifi c phosphatase 2) [70] .
It was recently reported that canonical Wnt signaling, a critical positive regulator of osteoblast diff erentiation, rapidly induces the expression of miR-29a and -29c [65] . Since activation of canonical Wnt signaling tends to increase during osteoblast diff erentiation, it is possible that Wnt signaling plays a role in the increased expression of miR-29 observed during osteoblast diff erentiation [71] . Further, miR-29a modulates canonical Wnt signaling in a positive feedback loop, to promote human osteoblast diff erentiation [72] . In human osteoblasts, transcription of miR-29a is induced by canonical Wnt signaling, and two T-cell factor/lymphoid enhancer factor (TCF/LEF) binding sites in the miR-29a promoter region are necessary for this induction. miR-29a was also found to target three inhibitors of Wnt signaling, Dkk1 (dikkopf-1), Kremen2 (kringle domain-containing transmembrane protein), and sFRP2 (secreted frizzled related protein 2). Th us, the induction of miR-29a transcription, in response to canonical Wnt signaling, results in decreased Dkk1, Kremen2, and sFRP2 levels, which potentiates Wnt signal ing. Th is loop provides an additional mechanism by which miR-29 can promote human osteoblast diff erentiation, and a mechanism for fi ne tuning the expression of specifi c components in the Wnt signaling pathway [71, 72] .
A similar study demonstrated that miR-27, which is increased during osteoblast diff erentiation, positively regu lates this process by targeting adenomatous polyposis coli (APC) [73] . In the absence of canonical Wnt signaling, APC is part of an inhibitor complex that binds β-catenin, preventing β-catenin translocation to the nucleus. Th is study suggests miR-27 promotes osteoblast diff erentiation by down-regulating APC, thus allowing for Wnt signaling. Indeed, over-expression of miR-27 increased ALP and osteocalcin, whereas its inhibition decreased these markers.
In the fi rst study assessing miRNAs and osteoporosis in humans, an inactivating mutation in miR-2861 was found to be associated with decreased serum markers of osteoblast activity in a kindred of osteoporosis patients [74] . Interestingly, miR-2861 appears to be a bone-enriched miRNA. It is highly expressed in osteoblasts, with a lower level of expression in liver. Knockdown of miR-2861 in mice resulted in decreased bone volume, bone formation rate and osteoblast surface. Conversely, increased expression of this miRNA in vitro augmented osteoblast diff erentiation. miR-2861 was shown to target the protein coding region of HDAC5. HDAC5 mediates deacetylation of Runx2 and deacetylated Runx2 undergoes Smurf1-mediated degradation [75] . Th erefore, HDAC5 inhibition by miR-2861 likely increases the abundance of acetylated Runx2, allowing for augmentation of osteoblast diff erentiation. Th is key study demonstrates the importance of miRNA genes and their contribution to human disease phenotypes.
Transcribed in the same pri-miRNA as miR-2861 is another novel miRNA, miR-3960. Th ese miRNAs likely work in concert, promoting osteoblastic diff erentiation by indirectly up-regulating Runx2 [76] . When miR-3960 is over-expressed, ALP, osteocalcin, and Runx2 are increased. Conversely, these diff erentiation markers are decreased when miR-3960 is inhibited. miR-3960 was found to directly target Hoxa2, a negative regulator of Runx2. Th us, the down-regulation of Hoxa2 by miR-3960 results in increased Runx2 expression. Further, Runx2 can bind the miR-3960 promoter, suggesting regulation of this miRNA cluster.
Overall, it is clear that miRNAs play an important role in osteoblast function and diff erentiation (summarized in Table 1 ). Future work, defi ning the function of particular miRNAs in osteoblast commitment and diff erentiation, could allow for the assembly of a panel of miRNAs that could be used as diff erentiation markers, similar to the panel of markers presently used to annotate the progression of diff erentiation, such as Runx2, ALP, osteocalcin, and osterix.
miRNAs in osteoclasts
Studies addressing the role of miRNAs in osteo clastogenesis are relatively limited. However, cell-type-specifi c deletion of Dicer at diff erent stages in the osteoclast lineage highlight the general importance of miRNAs in osteoclast function. For example, deletion of Dicer in mature osteoclasts, using a cathepsin K promoter drivenCre transgene in mice bearing fl oxed Dicer alleles, resulted in increased bone mass in the trabecular compart ment, due to a decrease in osteoclast number and surface [45] . Osteoclastogenesis in vitro was suppressed, suggesting a cell autonomous phenomenon. Interestingly, deletion of Dicer in mature osteoclasts also resulted in decreased bone formation rate, indicating an overall decrease in bone remodeling. Th ese authors reported that miRNA expression microarray analysis showed little change in the miRNA profi le in bone marrow macrophages (BMMs) treated for 24 hours with MCSF/RANKL to induce osteoclastogenesis. In this study, expression of miR-302c was stimulated to the greatest extent (approximately 1.8-fold), and this miRNA has been implicated in stem cell pluripotency [77] .
Similar results were obtained with Dicer knockdown in osteoclast precursors and mature osteoclasts [78] . Expres sion of a CD11b promoter driven-Cre transgene in mice bearing fl oxed Dicer alleles resulted in increased trabecular bone volume. Th e mice had decreased [78] .
Th is group also studied the function of miR-223 in osteoclastogenesis, since it is expressed in osteoclast precursors. Knockdown of miR-223 decreased the RANKL-induced formation of osteoclast-like cells in mouse RAW264.7 cells. However, over-expression of miR-223 also had a similar eff ect. Th ese data suggest that appropriate levels of miR-223 expression are important for normal osteoclastogenesis. Interestingly, knockdown of miR-223 resulted in an increase in NFI-A, a suppressor of osteoclastogenesis. Bioinformatics suggests that the 3' UTR for NFI-A may have a potential miR-223 binding site. Further, two PU.1 binding sites are present in the miR-223 promoter region [79] . Th e authors hypothesize that in osteoclast precursors, PU.1, induced by MCSF, may stimulate transcription of miR-223 and RANK. Mature miR-223 then likely targets NFI-A to increase expression of MCSF receptor, which is critical for osteoclast diff erentiation, function, and survival [80] .
Another group demonstrated increased association of cFos and PU.1 with the miR-21 promoter during osteo clast diff erentiation of mouse BMMs [81] . In BMMs transduced with a miR-21-antisense lentivirus, expres sion of PDCD4 (programmed cell death 4), a repressor of c-Fos, was increased. Th is eff ect correlated with decreased osteoclast diff erentiation markers, including c-Fos, cathepsin K, NFATc1, and TRAP staining, compared to controls.
In contra st, miR-155 acts as a molecular switch in monocytic cells to repress osteoclast formation and promote the macrophage fate [82] . miR-155 is downregulated in osteoclasts and up-regulated in macrophages. Over-expression of miR-155 in RAW 264.7 mono cytes blocked the formation of multinucleated osteo clasts, suppressed TRAP staining, blocked boneresorb ing activity, and increased macrophage diff erentiation. Conversely, knockdown of miR-155 caused an increase in osteoclasts and decrease in macrophages. Th e authors found that microphthalmia-associated transcription factor is a direct target of miR-155, and that it activates transcription of GPNMB (glycoprotein NMB, osteoactivin), a transmembrane protein critical for osteoclast diff erentiation. Th erefore, down-regulation of miR-155 is important for osteoclastogenesis.
As with osteoblasts, there is likely a panel of miRNAs important for osteoclast function and diff erentiation. More research will reveal these miRNAs and how they interact with signaling molecules to control osteoclast phenotypes.
Conclusion
Th ese studies represent the fi rst steps in demonstrating the importance of miRNAs in the control of osteoblast and osteoclast diff erentiation and function, and their role in bone turnover. An in-depth understanding of the roles of these regulatory RNAs in the skeleton will be critical for the development of new therapeutics aimed at treating bone loss and perhaps facilitating fracture repair. Although current therapies can be eff ective at preventing bone loss, there are patients who are refractory to treatment. Th e inhibition or over-expression of certain miRNAs in a tissue-specifi c manner has shown some promise in the treatment of tumors in animal models, and miRNA-based therapeutics have recently gone into clinical trials [83] . Th ere are two obvious benefi ts of miRNA-based therapeutics. miRNA oligonucleotide inhibitors or mimics can be targeted to specifi c tissues using relatively non-toxic delivery vehicles. In addition, these molecules can be relatively cost-eff ective compared to current peptide-based therapies. Much more work needs to be done to determine which miRNAs are important in bone, and to defi ne their roles in bone remodeling, fracture repair, and bone-related diseases.
